The transdermal medical patch market is projected to reach US$ 10,799.74 million by 2028 from US$ 8,247.21 million in 2022. It is expected to register a CAGR of 4.0% from 2023 to 2028.
Analyst Perspective
The rising prevalence of chronic diseases and growing consumption of tobacco drive the transdermal medical patch market growth. The rising number of patients suffering from chronic conditions and increasing activities in research and development, are the key factors propelling the market for transdermal medical patches. Additionally, increasing activities in research and development, are expected to boost the transdermal medical patch market growth. Furthermore, the transdermal medical patch market key players are focusing on strategic initiatives by launching new products to expand their geographic reach and enhance capacities to cater to a large customer base. For instance, in March 2021, Hisamitsu Pharmaceutical Co., Inc. announced approval for the manufacturing and marketing of ZICTHORU Tapes 75 mg, transdermal, pain treatment NSAID patch for “cancer pain” in Japan. The product is a systemic transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. The product's efficacy and safety have been confirmed in clinical trials in patients with cancer pain.
Transdermal Medical Patch Market - Market Overview
A transdermal medical patch, also known as medicated patch or skin patch, is a type of medical device designed to deliver medications or other therapeutic substances through the skin and into the blood stream. These patches are typically thin, adhesive patches that applied directly to the skin allowing the medication to be absorbed gradually over a specified period. Transdermal patches provide a convenient method of medication administration. They can be applied to the skin and worn for a specified duration, often ranging for a few hours to several days, depending on the medication and desired therapeutic effect.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Transdermal Medical Patch Market: Strategic Insights
Market Size Value in US$ 8,247.21 million in 2022 Market Size Value by US$ 10,799.74 million by 2028 Growth rate CAGR of 4.0% from 2023 to 2028 Forecast Period 2023-2028 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Transdermal Medical Patch Market: Strategic Insights
| Market Size Value in | US$ 8,247.21 million in 2022 |
| Market Size Value by | US$ 10,799.74 million by 2028 |
| Growth rate | CAGR of 4.0% from 2023 to 2028 |
| Forecast Period | 2023-2028 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Driver
Increasing Prevalence of Chronic Diseases Drives Global Transdermal Medical Patch Market
According to the Centers for Disease Control and Prevention (CDC), chronic diseases such as heart disease, cancer, and diabetes account for a significant amount (US$ 4,100,000 million) in annual healthcare spending in the US. Transdermal medical patches are used to administer medications to people suffering from chronic diseases such as heart disease, stroke, diabetes, cancer, obesity, and arthritis. According to the World Health Organization (WHO), ~17.9 million people died from CVDs in 2019, representing 32% of all deaths recorded globally. 85% of CVD-related deaths were due to heart attacks. According to the same source, over three-quarters of CVD deaths occurred in low-and-middle-income countries in 2019, including 17 million premature deaths (under the age of 70) due to noncommunicable diseases; CVDs were a cause of death in 38% of the mortalities associated with noncommunicable diseases.
A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. It works by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.
Alzheimer's disease was officially listed as the sixth-leading cause of death in the US in 2019 and the seventh-leading cause of death in 2020 and 2021. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8%), aged 65 and older, have Alzheimer's dementia. The percentage of people with Alzheimer's dementia increases with age. 5% of people aged 65–74, 13.1% aged 75–84, and 33.3% aged 85 and above have Alzheimer's dementia. According to a published the “Global Prevalence of Young-Onset Dementia" report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30–64 years, or ~200,000 Americans in total. Thus, individuals with age less than 65 can also develop Alzheimer's dementia.
Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil, which are cholinesterase inhibitors, exhibit a dose–response relationship, with higher doses of the drugs demonstrating greater efficacy. As a small, lipophilic, and hydrophilic molecule, rivastigmine is chemically well-suited for transdermal delivery. The technology underlying the rivastigmine patch contributes to its discreetly small and thin appearance. Thus, the rivastigmine patch enables quick and easy access to high-dose efficacy.
Therefore, the increasing prevalence of chronic diseases catalyzes the demand for medical patches, thus surging transdermal medical patch market.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Transdermal Medical Patch Market - Segmental Analysis
Based on type, the transdermal medical patch market is segmented into single-layer drug in-adhesive, multi-layer drug in-adhesive, reservoir, vapor patch and matrix. The matrix segment held the largest market share in 2022, and the same segment is anticipated to register the highest CAGR of 5.3% during the forecast period. The market position of this segment is due to the patient compliance and convenience. The matrix patch is designed with features that further improve patient compliance, such as extended wear time, simplified application, or smart monitoring capabilities to track medication adherence. The matrix patch incorporates sensors or monitoring capabilities to provide real-time feedback on a patient’s health status.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Transdermal Medical Patch Market - Regional Analysis
Asia-Pacific is the dominating region in the transdermal medical patch market. The Asia-Pacific transdermal medical patch market was valued at US$ 2,024.32 million in 2022 and is projected to reach US$ 2,744.32 million by 2028; it is expected to grow at a CAGR of 5.2% during the forecast period. The Asia-Pacific transdermal medical patch market is segmented into China, the Japan, India, and the Rest of Asia-Pacific. The regional growth is attributed to growing research on cancer and gene mutations, increasing disease modeling, and developments by market players offering transdermal medical patch. Factors such as developing healthcare facilities, growing aging population to share key facts associated with stem cell technologies and increasing partnerships with foreign entities are likely to further propel the transdermal medical patch market growth during the forecast period.
Transdermal Medical Patch Market - Key Player Analysis
The transdermal medical patch market analysis consists of the players such as Hisamitsu Pharmaceutical Co Inc, Medline Industries LP, Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd, UCB SA, Viatris Inc, Endo Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, and Corium, LLC. Among the players in the transdermal medical patch market Hisamitsu Pharmaceutical Co Inc and Novartis AG are the top two players owing to the diversified product portfolio offered.
Transdermal Medical Patch Market - Recent Developments
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the transdermal medical patch market. A few recent key market developments are listed below:
- In 2019, Nitto Denko Corporation announced the Bisono Tape 2mg, transdermal patches containing a β1 blocker that was co-developed with Toa Eiyo Ltd., launched by Toa Eiyo and Astellas Pharma Inc.
- In June 2022, Hisamitsu Pharmaceutical Co., Inc. has been approved for the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU Tapes, transdermal, pain treatment NSAID patch in Japan. The product was approved for manufacturing and marketing approval for “analgesia in various cancer” in March 2021. This approval is based on the data of Phase III clinical studies that evaluated the efficacy and safety of the product in patients with low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis. With this approval of the additional indications, Hisamitsu expects the product to be a new option for the treatment of low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis.
- In January 2021, Hisamitsu Pharmaceutical Co., Inc. has commenced the Phase III clinical study in the U.S. for transdermal, pain relief and anti-inflammatory patch for the treatment of Osteoarthritis knee pain. The clinical study will be conducted by the U.S. subsidiary, Noven Pharmaceuticals, Inc. The investigational product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu Pharmaceutical hopes the investigational product will be a new treatment option for Osteoarthritis of the knee, demonstrating efficacy and safety by achieving higher drug delivery to the affected area as one of the transdermal formulation attributes.
- In September 2022, Corium, Inc launched ADLARITY (donepezil transdermal system) and is now available for prescription in the U.S. for treating patients with mild, moderate, or severe dementia of Alzheimer's type.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The transdermal medical patch market majorly consists of the players, such as Hisamitsu Pharmaceutical Co Inc, Medline Industries LP, Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd, UCB SA, Viatris Inc, Endo Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, and Corium, LLC.
The transdermal medical patch market is estimated to be valued at US$ 8,247.21 million in 2022.
The transdermal medical patch is a medicated patch that can deliver drugs through skin portals directly to the bloodstream at a predetermined rate. This is the most comfortable dosage form – it is non-invasive, avoids the gastrointestinal tract and bypasses first-pass metabolism, can have multiday therapy, and can be terminated at any time.
The matrix segment held the largest share of the market in 2022. Also, the same segment is estimated to register the highest CAGR in the market during the forecast period.
The CAGR value of the transdermal medical patch market during the forecasted period of 2023-2028 is 4.0%.
The factors that are driving the growth of the transdermal medical patch market are the increasing aging population, increasing prevalence of chronic diseases and growing consumption of tobacco and increasing partnerships with foreign entities. These are some of the major factors contributing to the growth of the transdermal medical patch industry.
The Asia Pacific is expected to be the fastest-growing region in the transdermal medical patch market over the forecast period due to the increasing prevalence of chronic diseases and the growing research on cancer and gene mutations, increasing disease modeling, and developments by market players offering transdermal medical patch.
The transdermal medical patch market is expected to be valued at US$ 10,799.74 million in 2028.
The List of Companies - Transdermal Medical Patch Market
- Hisamitsu Pharmaceutical Co Inc
- Medline Industries LP
- Johnson & Johnson
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- UCB SA
- Viatris Inc
- Endo Pharmaceuticals Inc
- Boehringer Ingelheim International GmbH
- Corium, LLC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Transdermal Medical Patch Market
Jun 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jun 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jun 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)